A Review on Antiviral Activity of Favipiravir
Mariya Palathingal, M. Archana, K. Athulya Damodharan, . Nuaman, P. Ashisha, Akash Marathakam
Journal of Pharmaceutical Research International · pp. 1–7 · Published 24 Jan 2022
10.9734/jpri/2022/v34i3B35387Abstract
The emerging severe acute respiratory syndrome coronavirus 2 pandemic endangers patients and physicians all over the world. The potency of COVID-19 antiviral drugs is still a matter of debate. The growing understanding of COVID-19 virology and clinical manifestations is resulting in a larger pool of potential pharmacological targets. Favipiravir is included in the treatment regimen of many countries, including some regions of India, that have recently updated their treatment standards and is expected to be an effective treatment for SARS-CoV-2 infection, as it can be used to treat many different types of RNA virus infections such as Ebola, influenza, and the foot-and-mouth disease virus can be treated with this new nucleoside analogue. This review describes the status, mechanisms, pharmacokinetics, and antiviral effect of Favipiravir.
Cited by 5
Tatiana P. Gerasimova, Aliya M. Saitova, Almaz A. Zagidullin · Journal of Molecular Liquids · 2025
Hasan Aydın, Uğur Uslu, Süleyman Akocak · ChemistrySelect · 2023
Showing 2 of 5 known citations — external sources report more than can currently be individually listed.
Related research
- Covid-2019:“A Microbiological Monster” — shares topic coverage
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Using Ultraviolet A to Check Inanimate Objects for Thorough Cleanliness during COVID-19 Pandemic — shares topic coverage
- The Evaluation of Biochemical Parameters in Positive COVID-19 RealTime PCR Patients: A Retrospective Study — shares topic coverage
- Characteristics of the New Coronavirus Named SARS-CoV-2 Responsible for an Infection Called Coronavirus Disease 2019 (COVID-19) — shares topic coverage
Article metrics
Real usage data collected on this platform.
6
Page views
0
PDF downloads
0
Outbound clicks
5
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.